Cooperative Agreement 2423415
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$1M
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Dorchester, MA 02125, USA
Similar Awards
This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...
This $1,008,000 Cooperative Agreement award was provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a high-throughput platform for screening millions of T-cell receptors (TCRs) against a large set of clinically relevant cancer antigens, in order to identify and validate promising TCRs for cancer-specific cell killing. The goal is to discover and validate multiple anti-cancer TCRs that could...
This Cooperative Agreement award from the National Science Foundation (NSF), under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $1,250,000 in funding to Rattan Life Science Inc., a self-certified small disadvantaged business, for the development and validation of a novel platform technology to enable the scalable generation of high-quality, tumor-targeted induced naïve T cells for off-the-shelf cancer immunotherapies. The project aims to increase the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...
The National Science Foundation (NSF) awarded a $1,213,619 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Encapsulate Inc., a small disadvantaged business in Farmington, CT. This Phase II Small Business Innovation Research (SBIR) project aims to develop a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models to predict patient-specific cancer drug responses. The proposed technology utilizes...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant of $305,000 awarded to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to design and synthesize new therapeutic payloads that can selectively target and destroy therapy-resistant cancer cells. Research objectives include testing the effectiveness and selectivity of the payload...
This $275,000 federal Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of Illuminate Therapeutics' Light Activated Drug Delivery and Release (LADDR) platform technology. The LADDR platform aims to enable precise spatiotemporal delivery of small therapeutic RNAs to tumors in head and neck and esophageal cancers, with the goal of preserving healthy tissues and reducing side effects compared to...
This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $990,477 in funding to Drive Therapeutics L.L.C. to optimize the manufacturing efficiency of bispecific aptamer therapeutics for treating retinal diseases such as wet age-related macular degeneration and diabetic macular edema. The project aims to enhance the efficacy and reduce the treatment burden of these therapies compared to the...